Literature DB >> 7719916

Serotypes and subtypes of Neisseria meningitidis: results of an international study comparing sensitivities and specificities of monoclonal antibodies.

J T Poolman1, P Kriz-Kuzemenska, F Ashton, W Bibb, J Dankert, A Demina, L O Frøholm, M Hassan-King, D M Jones, I Lind.   

Abstract

An international study supported by the World Health Organization comparing monoclonal antibodies for serotyping and serosubtyping of Neisseria meningitidis strains was performed and the results were assessed in 1992. A collection of 6 serotype-specific (1, 2a, 2b, 4, 14, and 15) and 12 serosubtype-specific (P1.1, P1.2, P1.4, P1.5, P1.6, P1.7, P1.9, P1.10, P1.12, P1.14, P1.15, and P1.16) monoclonal antibodies was provided to 11 participating laboratories throughout the world. Monoclonal antibodies were tested on 85 Neisseria meningitidis strains with known reference results. Whole-cell enzyme-linked immunosorbent assay was used for analysis in 10 of 11 laboratories. The sensitivities and specificities of individual serotype- and subtype-specific monoclonal antibodies were evaluated. Differences in individual laboratories and with individual monoclonal antibodies were assessed. Relatively large differences in sensitivities were achieved in individual laboratories. On the contrary, the specificities remained at high levels in all laboratories. The sensitivities of serotype-specific monoclonal antibodies ranged from 72.0 to 100%. Individual serosubtype-specific monoclonal antibodies showed sensitivities ranging from 64.1 to 98.1%. The most frequent reason for the incorrect results obtained with the monoclonal antibodies were false-negative results. The collaborative study demonstrated that some monoclonal antibodies are not very sensitive. Another study to define the most suitable monoclonal antibodies is planned.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7719916      PMCID: PMC170103          DOI: 10.1128/cdli.2.1.69-72.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  14 in total

1.  Sero-subtyping of group B, C, Y and A meningococci isolated in France in 1988.

Authors:  J Y Riou; J T Poolman; J Auriol; F Lomprez; M Guibourdenche
Journal:  Ann Biol Clin (Paris)       Date:  1990       Impact factor: 0.459

2.  Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway.

Authors:  G Bjune; E A Høiby; J K Grønnesby; O Arnesen; J H Fredriksen; A Halstensen; E Holten; A K Lindbak; H Nøkleby; E Rosenqvist
Journal:  Lancet       Date:  1991-11-02       Impact factor: 79.321

Review 3.  Serotype antigens of Neisseria meningitidis and a proposed scheme for designation of serotypes.

Authors:  C E Frasch; W D Zollinger; J T Poolman
Journal:  Rev Infect Dis       Date:  1985 Jul-Aug

4.  Outer membrane protein serosubtyping of Neisseria meningitidis.

Authors:  J T Poolman; H Abdillahi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

5.  Serological study of meningococcal isolates in Switzerland and France 1980-1986.

Authors:  P Calain; J Poolman; W Zollinger; G Sperber; D Bitter-Suermann; R Auckenthaler; B Hirschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-12       Impact factor: 3.267

6.  Neisseria meningitidis group B serosubtyping using monoclonal antibodies in whole-cell ELISA.

Authors:  H Abdillahi; J T Poolman
Journal:  Microb Pathog       Date:  1988-01       Impact factor: 3.738

7.  [Serotyping and subtyping strains of Neisseria meningitidis isolated from patients in Czechoslovakia 1975-1986].

Authors:  P Kuzemenská; M Bobák
Journal:  Cesk Epidemiol Mikrobiol Imunol       Date:  1990-03

8.  Meningococcal disease in The Netherlands, 1958-1990: a steady increase in the incidence since 1982 partially caused by new serotypes and subtypes of Neisseria meningitidis.

Authors:  R J Scholten; H A Bijlmer; J T Poolman; B Kuipers; D A Caugant; L Van Alphen; J Dankert; H A Valkenburg
Journal:  Clin Infect Dis       Date:  1993-02       Impact factor: 9.079

9.  Meningococcal serotypes and serogroup B disease in north-west Europe.

Authors:  J T Poolman; I Lind; K Jónsdóttir; L O Frøholm; D M Jones; H C Zanen
Journal:  Lancet       Date:  1986-09-06       Impact factor: 79.321

10.  Human immunity to the meningococcus. I. The role of humoral antibodies.

Authors:  I Goldschneider; E C Gotschlich; M S Artenstein
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  14 in total

1.  Evaluation of porB PCR-amplicon restriction endonuclease analysis as a method to determine porB variable-region sequences in nonserotypeable meningococci.

Authors:  Kristin H Dyet; Robin S Simmonds; Diana R Martin
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

2.  The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance.

Authors:  Guillermo Madico; Jo Anne Welsch; Lisa A Lewis; Anne McNaughton; David H Perlman; Catherine E Costello; Jutamas Ngampasutadol; Ulrich Vogel; Dan M Granoff; Sanjay Ram
Journal:  J Immunol       Date:  2006-07-01       Impact factor: 5.422

3.  Phase variation mediates reductions in expression of surface proteins during persistent meningococcal carriage.

Authors:  Mohamed Alamro; Fadil A Bidmos; Hannah Chan; Neil J Oldfield; Emma Newton; Xilian Bai; Jack Aidley; Rory Care; Claire Mattick; David P J Turner; Keith R Neal; Dlawer A A Ala'aldeen; Ian Feavers; Ray Borrow; Christopher D Bayliss
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

4.  Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United States. The Active Bacterial Core Surveillance Team.

Authors:  M L Tondella; T Popovic; N E Rosenstein; D B Lake; G M Carlone; L W Mayer; B A Perkins
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

5.  Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Tsegaye Alebel; Degu Berhanu; Morten Harboe; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2007-02-14

6.  Antigenic diversity of meningococcal outer membrane protein PorA has implications for epidemiological analysis and vaccine design.

Authors:  I M Feavers; A J Fox; S Gray; D M Jones; M C Maiden
Journal:  Clin Diagn Lab Immunol       Date:  1996-07

7.  Phenotypic and genotypic approaches to characterization of isolates of Neisseria meningitidis from patients and their close family contacts.

Authors:  G Tzanakaki; R Urwin; M Musilek; P Kriz; J Kremastinou; A Pangalis; C C Blackwell; M C Maiden
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

8.  Molecular subtyping of Neisseria meningitidis serogroup B: comparison of five methods.

Authors:  B Swaminathan; G M Matar; M W Reeves; L M Graves; G Ajello; W F Bibb; L O Helsel; M Morales; H Dronavalli; M el-Swify; W DeWitt; S B Hunter
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

9.  Construction of Opa-positive and Opa-negative strains of Neisseria meningitidis to evaluate a novel meningococcal vaccine.

Authors:  Manish Sadarangani; J Claire Hoe; Martin J Callaghan; Claire Jones; Hannah Chan; Katherine Makepeace; Hélène Daniels-Treffandier; Mary E Deadman; Christopher Bayliss; Ian Feavers; Peter van der Ley; Andrew J Pollard
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

10.  Phase variation of PorA, a major outer membrane protein, mediates escape of bactericidal antibodies by Neisseria meningitidis.

Authors:  Isfahan Tauseef; Youssif M Ali; Christopher D Bayliss
Journal:  Infect Immun       Date:  2013-02-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.